PDCD1 and T-cell non-Hodgkin lymphoma: assessed the safety and activity of another programmed cell death protein 1 inhibitor plus P-GemOx (pegaspargase, gemcitabine, and oxaliplatin) in the first-line setting for advanced extranodal natural killer/T-cell lymphoma, also showing safeness and activity in this case (32).